PDCD1 and glioblastoma: A phase 1 clinical trial NCT02658981 showed that using anti-LAG-3 monoclonal antibody BMS-986016 or BMS-663513 (anti-CD137) can improve the survival rate in patients with recurrent GBM, when combined with anti-PD-1 [86] (Table 1).